| Literature DB >> 15533242 |
Richard L Nelson1, Alan Schwartz.
Abstract
BACKGROUND: Due to the low participation in colorectal cancer screening, public preference for colorectal cancer screening modality was determined.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15533242 PMCID: PMC533878 DOI: 10.1186/1471-2407-4-76
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Surveys of screening preference for colorectal cancer
| Steine9 | GI Patients 45–79 y | 190 | BE v C | BE | Post hoc |
| Durdey10 | GI Patients 19–88 y | 66 | BE v C | C | Post hoc |
| VanNess11 | GI Patients 20–84 y | 189 | BE v C | C | Post hoc |
| Elwood20 | Relatives of GI Patients 45–70 y | 232 | FS v C | FS = C | RCT; Subjects offered FS or C and differential compliance measured |
| Dominitz12 | VAOP 50–75 y | 62 | FS v C | FS | Time trade off measure Least for FS. |
| Frew13 | PCOP >25 y | 2294 | FOBT v FS | FOBT | Willingness to pay primary endpoint. Preference also collected. |
| Leard14 | PCOP 50–75 y | 100 | FOBT, FS, BE, C | C preferred FOBT more likely to be done. | Post hoc 93% previously screened |
| Dolan17 | PCOP >50 y | 96 | FOBT, FS, BE, C | FOBT | DARCT |
| Pignone15 | PCOP 50–75 y | 227 | FOBT v FS | FOBT | DARCT |
| Pignone18 | PCOP 50–75 y | 146 | FOBT v FS | FOBT | 4 levels of survey after varying quantities of information on colon cancer risk, conduct, test accuracy, cost. |
| Wolf16 | PCOP >65 y | 57 | FOBT v FS | FOBT | DARCT |
| Nelson | Non-patients 18–54 y | 80 | FOBT, FS, BE, C | FOBT |
GI Patients; Gastroenterology patients
BE; Barium enema.
C; Colonoscopy
FS; Fiberoptic sigmoidoscopy
FOBT; Fecal Occult Blot Testing
Post hoc; Preference measured after undergoing one or more of the above screening tests.
RCT; Randomised Controlled Trial
VAOP; Veteran's administration hospital outpatients
PCOP; Primary care outpatients
DARCT; Randomised trial to investigate the effectiveness of decision aids in increasing screening participation
Mean test ranks for each domain of preference of colorectal cancer screening test
| Dimensions | |||||
| Test Modality | Preference | Physical Discomfort | Inconvenience | Embarrassment | Danger |
| Colonoscopy | 3.14 | 3.37 | 3.47 | 3.14 | 3.56 |
| Barium Enema | 2.87 | 3.09 | 2.97 | 3.12 | 3.56 |
| Fiberoptic Sigmoidoscopy | 2.38 | 2.46 | 2.04 | 2.40 | 2.32 |
| Fecal Occult Blood Test | 1.61 | 1.09 | 1.52 | 1.34 | 1.09 |
| Friedman's test χ2 (3 df) | 62.7* | 146.6* | 110.9* | 102.4* | 162.8* |
| Wilcoxon signed-ranks Z (FOBT vs. FS) | 4.1* | 7.2* | 3.2* | 5.3* | 7.5* |
| N = | 77 | 79 | 79 | 78 | 79 |
Notes: Mean ranks for each test on each of the dimensions. Lower mean ranks refer to greater preference, and less discomfort, inconvenience, embarrassment, or danger. A * indicates test statistics that are significant at p < 0.05.
N = ; Less than 80 responses due to blank forms.
Mean test ranks for each domain of preference of colorectal cancer screening test:: individuals who have experienced none of the tests
| Dimensions | |||||
| Test Modality | Preference | Physical Discomfort | Inconvenience | Embarrassment | Danger |
| Colonoscopy | 3.13 | 3.42 | 3.56 | 3.07 | 3.57 |
| Barium enema | 2.83 | 3.11 | 2.98 | 3.15 | 3.05 |
| Fiberoptic sigmoidoscopy | 2.35 | 2.45 | 1.91 | 2.38 | 2.32 |
| Faecal occult blood test | 1.69 | 1.02 | 1.55 | 1.40 | 1.05 |
| Friedman's test χ2 (3 df) | 38.7* | 112.6* | 86.6* | 65.9* | 118.4* |
| Wilcoxon signed-ranks Z (FOBT vs. FS) | 3.2* | 6.5* | 2.0* | 4.3* | 6.6* |
| N = | 54 | 55 | 55 | 54 | 55 |
Notes: Mean ranks for each test on each of the dimensions. Lower mean ranks refer to greater preference, and less discomfort, inconvenience, embarrassment, or danger. A * indicates test statistics that are significant at p < 0.05.
N = ; Less than 57 due to blank responses